These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32612257)

  • 1. Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients.
    Barakat AK; Scholl C; Steffens M; Brandenburg K; Ising M; Lucae S; Holsboer F; Laje G; Kalayda GV; Jaehde U; Stingl JC
    Transl Psychiatry; 2020 Jul; 10(1):210. PubMed ID: 32612257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression and proliferation biomarkers for antidepressant treatment resistance.
    Breitfeld J; Scholl C; Steffens M; Laje G; Stingl JC
    Transl Psychiatry; 2017 Mar; 7(3):e1061. PubMed ID: 28291260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
    Li QS; Tian C; Seabrook GR; Drevets WC; Narayan VA
    Transl Psychiatry; 2016 Sep; 6(9):e889. PubMed ID: 27622933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
    Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
    J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
    Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
    Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker.
    Morag A; Pasmanik-Chor M; Oron-Karni V; Rehavi M; Stingl JC; Gurwitz D
    Pharmacogenomics; 2011 Feb; 12(2):171-84. PubMed ID: 21332311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study.
    Probst-Schendzielorz K; Scholl C; Efimkina O; Ersfeld E; Viviani R; Serretti A; Fabbri C; Gurwitz D; Lucae S; Ising M; Paul AM; Lehmann ML; Steffens M; Crisafulli C; Calabrò M; Holsboer F; Stingl J
    Pharmacogenomics; 2015; 16(7):689-701. PubMed ID: 25943212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study.
    Leuchter AF; Cook IA; Marangell LB; Gilmer WS; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; McCracken JT; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):124-31. PubMed ID: 19712979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics studies in STAR*D: strengths, limitations, and results.
    Laje G; Perlis RH; Rush AJ; McMahon FJ
    Psychiatr Serv; 2009 Nov; 60(11):1446-57. PubMed ID: 19880459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study.
    Souery D; Serretti A; Calati R; Oswald P; Massat I; Konstantinidis A; Linotte S; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    World J Biol Psychiatry; 2011 Aug; 12(5):364-75. PubMed ID: 21718212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
    Fava M; Rush AJ; Alpert JE; Balasubramani GK; Wisniewski SR; Carmin CN; Biggs MM; Zisook S; Leuchter A; Howland R; Warden D; Trivedi MH
    Am J Psychiatry; 2008 Mar; 165(3):342-51. PubMed ID: 18172020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.
    Davis LL; Wisniewski SR; Howland RH; Trivedi MH; Husain MM; Fava M; McGrath PJ; Balasubramani GK; Warden D; Rush AJ
    Drug Alcohol Depend; 2010 Mar; 107(2-3):161-70. PubMed ID: 19945804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T3 augmentation of SSRI resistant depression.
    Abraham G; Milev R; Stuart Lawson J
    J Affect Disord; 2006 Apr; 91(2-3):211-5. PubMed ID: 16483669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.
    Köhler-Forsberg O; Larsen ER; Buttenschøn HN; Rietschel M; Hauser J; Souery D; Maier W; Farmer A; McGuffin P; Aitchison KJ; Uher R; Mors O
    Br J Psychiatry; 2019 Aug; 215(2):494-501. PubMed ID: 30698114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.
    Eyre HA; Eskin A; Nelson SF; St Cyr NM; Siddarth P; Baune BT; Lavretsky H
    Int J Geriatr Psychiatry; 2016 May; 31(5):510-7. PubMed ID: 26471432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers.
    Oved K; Morag A; Pasmanik-Chor M; Oron-Karni V; Shomron N; Rehavi M; Stingl JC; Gurwitz D
    Pharmacogenomics; 2012 Jul; 13(10):1129-39. PubMed ID: 22909203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.
    Guilloux JP; Bassi S; Ding Y; Walsh C; Turecki G; Tseng G; Cyranowski JM; Sibille E
    Neuropsychopharmacology; 2015 Feb; 40(3):701-10. PubMed ID: 25176167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.
    Kornstein SG; Toups M; Rush AJ; Wisniewski SR; Thase ME; Luther J; Warden D; Fava M; Trivedi MH
    J Womens Health (Larchmt); 2013 Feb; 22(2):121-31. PubMed ID: 23398127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.